GlassScriptPhysician profile
Ananthram P Reddy
NPI 1124014923
$5,767.65
in general payments reported to CMS, 2019-2025
27 companies · $2,379 in 2025
The $2,379 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $549 · 2021: $242 · 2022: $728 · 2023: $540 · 2024: $548 · 2025: $2,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.09 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Medical Systems Corporation | $1,500.00 | 2025 | Evis Exera III Duodenovideoscope |
| Abbvie INC. | $1,451.37 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $547.25 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.78 | 2019-2025 | Trulance, Xifaxan |
| Pfizer INC. | $301.02 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $194.94 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $185.90 | 2020-2024 | |
| Qol Medical, LLC | $150.63 | 2019-2022 | |
| Dova Pharmaceuticals | $146.13 | 2019 | |
| Portola Pharmaceuticals, LLC | $126.35 | 2020 | |
| Aimmune Therapeutics, INC. | $124.56 | 2025 | Zenpep |
| Gilead Sciences, INC. | $109.91 | 2025 | Livdelzi |
| Ardelyx, INC. | $81.02 | 2024 | Ibsrela |
| Allergan, INC. | $79.95 | 2019-2020 | |
| Celltrion USA INC. | $69.81 | 2024-2025 | Vegzelma |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $66.24 | 2024 | Voquezna |
| Medtronic, INC. | $41.88 | 2025 | Endoflip |
| Intercept Pharmaceuticals, INC. | $41.59 | 2019-2020 | |
| Redhill Biopharma INC. | $33.63 | 2020 | |
| Ferring Pharmaceuticals INC. | $31.72 | 2023 | Rebyota |
| Novo Nordisk INC | $26.78 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $24.14 | 2019 | |
| Capsovision, INC. | $22.00 | 2023 | Capsocam Plus |
| Boston Scientific Corporation | $20.82 | 2023 | Orcapod |
| Merck Sharp & Dohme LLC | $15.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.73 | 2021 | |
| Braintree Laboratories, INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ananthram Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.